{"id":"https://openalex.org/W4361819233","doi":"https://doi.org/10.1158/1078-0432.22443291","title":"Supplementary Table 1 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma","display_name":"Supplementary Table 1 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361819233","doi":"https://doi.org/10.1158/1078-0432.22443291"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22443291","doi":"https://doi.org/10.1158/1078-0432.22443291","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22443291","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Pretargeted_Radioimmunotherapy_Using_Genetically_Engineered_Antibody-Streptavidin_Fusion_Proteins_for_Treatment_of_Non-Hodgkin_Lymphoma/22443291/1/files/39894252.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Pretargeted_Radioimmunotherapy_Using_Genetically_Engineered_Antibody-Streptavidin_Fusion_Proteins_for_Treatment_of_Non-Hodgkin_Lymphoma/22443291/1/files/39894252.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112904385","display_name":"Steven I. Park","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven I. Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089665460","display_name":"Jaideep Shenoi","orcid":"https://orcid.org/0000-0001-8465-3479","observed_orcids":["https://orcid.org/0000-0001-8465-3479"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jaideep Shenoi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062268407","display_name":"Shani L. Frayo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shani M. Frayo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112459717","display_name":"Donald K. Hamlin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald K. Hamlin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053467199","display_name":"Yukang Lin","orcid":"https://orcid.org/0000-0001-8586-8682","observed_orcids":["https://orcid.org/0000-0001-8586-8682"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yukang Lin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"D. Scott Wilbur","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Scott Wilbur","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064390595","display_name":"Patrick S. Stayton","orcid":"https://orcid.org/0000-0001-6939-6371","observed_orcids":["https://orcid.org/0000-0001-6939-6371"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick S. Stayton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084626966","display_name":"Nural N. Orgun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nural Orgun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059780147","display_name":"Mark D. Hylarides","orcid":"https://orcid.org/0000-0002-5968-9872","observed_orcids":["https://orcid.org/0000-0002-5968-9872"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Hylarides","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105190730","display_name":"Franz Buchegger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Franz Buchegger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110744129","display_name":"Aimee L. Kenoyer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aimee L. Kenoyer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014614433","display_name":"Amanda Axtman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amanda Axtman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ajay K. Gopal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007024434","display_name":"Damian J. Green","orcid":"https://orcid.org/0000-0003-0477-1446","observed_orcids":["https://orcid.org/0000-0003-0477-1446"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Damian J. Green","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040412322","display_name":"John M. Pagel","orcid":"https://orcid.org/0000-0001-5745-8125","observed_orcids":["https://orcid.org/0000-0001-5745-8125","https://orcid.org/0000-0003-2875-4878"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John M. Pagel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5023180146","display_name":"Oliver W. Press","orcid":"https://orcid.org/0000-0002-3147-8037","observed_orcids":["https://orcid.org/0000-0002-3147-8037"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Oliver W. Press","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pretargeted-radioimmunotherapy","display_name":"pretargeted radioimmunotherapy","score":0.9620000123977661},{"id":"https://openalex.org/keywords/genetically-engineered-antibodies","display_name":"genetically engineered antibodies","score":0.843999981880188},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9490000009536743},{"id":"https://openalex.org/keywords/targeted-radiotherapy","display_name":"targeted radiotherapy","score":0.48399999737739563}],"concepts":[{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.9054579138755798},{"id":"https://openalex.org/C123894998","wikidata":"https://www.wikidata.org/wiki/Q425158","display_name":"Fusion protein","level":4,"score":0.5844212770462036},{"id":"https://openalex.org/C2776190903","wikidata":"https://www.wikidata.org/wiki/Q421817","display_name":"Streptavidin","level":3,"score":0.5385855436325073},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5276103019714355},{"id":"https://openalex.org/C3019111730","wikidata":"https://www.wikidata.org/wiki/Q159236","display_name":"Genetically engineered","level":3,"score":0.5123923420906067},{"id":"https://openalex.org/C158525013","wikidata":"https://www.wikidata.org/wiki/Q2593739","display_name":"Fusion","level":2,"score":0.45358920097351074},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4412826597690582},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4025425910949707},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.34615397453308105},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3180410861968994},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.27671000361442566},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2287941575050354},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.1562691628932953},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13462263345718384},{"id":"https://openalex.org/C2778204606","wikidata":"https://www.wikidata.org/wiki/Q181354","display_name":"Biotin","level":2,"score":0.09826001524925232},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.05736425518989563},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C41895202","wikidata":"https://www.wikidata.org/wiki/Q8162","display_name":"Linguistics","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22443291","doi":"https://doi.org/10.1158/1078-0432.22443291","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22443291","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Pretargeted_Radioimmunotherapy_Using_Genetically_Engineered_Antibody-Streptavidin_Fusion_Proteins_for_Treatment_of_Non-Hodgkin_Lymphoma/22443291/1/files/39894252.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22443291.v1","doi":"https://doi.org/10.1158/1078-0432.22443291.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22443291.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22443291","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Pretargeted_Radioimmunotherapy_Using_Genetically_Engineered_Antibody-Streptavidin_Fusion_Proteins_for_Treatment_of_Non-Hodgkin_Lymphoma/22443291","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22443291","doi":"https://doi.org/10.1158/1078-0432.22443291","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22443291","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Pretargeted_Radioimmunotherapy_Using_Genetically_Engineered_Antibody-Streptavidin_Fusion_Proteins_for_Treatment_of_Non-Hodgkin_Lymphoma/22443291/1/files/39894252.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361819233.pdf","grobid_xml":"https://content.openalex.org/works/W4361819233.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2031326397","https://openalex.org/W1978938554","https://openalex.org/W2107861907","https://openalex.org/W302750429","https://openalex.org/W2589564541","https://openalex.org/W4361819189","https://openalex.org/W264391706","https://openalex.org/W4300913617","https://openalex.org/W2138994942","https://openalex.org/W1982849241"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2023-04-05T00:00:00"}